^
Association details:
| Biomarker: | Chr t(11;14) |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + Tecentriq (atezolizumab) (PD-L1 inhibitor) + Cotellic (cobimetinib) (MEK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma
Excerpt:
...Percentage of Participants With Adverse Events (AEs)`ORR was defined as a stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) and was analyzed in the safety evaluable population and in the biomarker-selected sub-populations of t(11;14) and RAS mutations.`...
Trial ID:
Source:
Title:
Safety and Preliminary Efficacy Results from a Phase Ib/II Study of Cobimetinib As a Single Agent and in Combination with Venetoclax with or without Atezolizumab in Patients with Relapsed/Refractory Multiple Myeloma
Published date:
11/04/2020
Excerpt:
Compared with the non-t(11;14) pts, responses to C+V and C+V+A were higher among t(11;14) pts, with an ORR of 50% (2/4) and 100% (5/5), respectively….Preliminary efficacy results show moderate activity of the combinations in all-comers and higher activity in t(11;14) pts, supporting a biomarker-driven approach in the development of V in MM.
Trial ID:
